ABSTRACT
INTRODUCTION AND OBJECTIVE: In situation with the COVID-19 outbreak, the EAU guidelines Rapid Reaction Group provided recommendations to guide muscle invasive bladder cancer (MIBC) priorities, and they recommended that neoadjuvant chemotherapy should be considered omitted in T2/3 focal N0M0 MIBC patients. This meta-analysis aims to evaluate the efficacy of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of T2-4aN0M0 MIBC patients. METHODS: Following the PRISMA guideline, PubMed, EMBASE, and Cochrane Library were searched up to September 2021. The articles were searched with keywords muscle-invasive bladder cancer, neoadjuvant chemotherapy, cystectomy, and overall survival. Participants, patients with T2-4aN0M0 MIBC;Interventions, T2- 4aN0M0 MIBC patients who underwent neoadjuvant chemotherapy;Outcomes, comparison of overall survival included for analysis. The overall survival was analyzed as hazard ratio (HR) and 95% confidence interval (CI) and presented in a forest plot. We also conducted a sub-analysis of only T2N0M0 MIBC patients. Quality assessments were performed independently by two reviewers using the Scottish Intercollegiate Guidelines Network. RESULTS: A total of 8 studies were included in the metaanalysis. 8 studies were intermediate risk for detection bias and there were no major problems. In T2-4aN0M0 MIBC patients, the overall survival was significantly better in the neoadjuvant chemotherapy + radical cystectomy group than in the radical cystectomy alone group (HR, 0.79;95% CI, 0.69-0.92;p=0.002) (Fig. 1A). A subgroup analysis was performed on only T2N0M0 MIBC patients and 5 studies were included. There was no difference in overall survival between the neoadjuvant chemotherapy + radical cystectomy group and the radical cystectomy alone group (HR, 0.83;95% CI, 0.69-1.02;p=0.06) (Fig. 1B). CONCLUSIONS: As recommended by the EAU guidelines Rapid Reaction Group, it is thought that patients with T2N0M0 MIBC should strongly consider omitting neoadjuvant chemotherapy until the end of the COVID-19 pandemic. Whether to omit neoadjuvant in T2- 4aN0M0 MIBC should be discussed further, and studies targeting only T2-3N0M0 MIBC are expected to proceed further.
ABSTRACT
Introduction & Objectives: During coronavirus disease 2019 (COVID-19) pandemic, EAU recommended intravesical bacillus Calmette-Guérin (BCG) therapy courses that have been ongoing for longer than 1 year can be safely terminated for high-risk non-muscle-invasive bladder cancer(NMIBC) patients. Thus, we conducted a systematic review and network meta-analysis according to EAU COVID-19 recommendation.Materials & Methods: Systematic review was performed following the PRISMA guideline. PubMed/Medline, EMBASE, and Cochrane Library weresearched up to Sep, 2021. We conducted a network meta-analysis to outcomes including only induction therapy group (No_M), 1-year (M1) andmore than 1 year (MM1) maintenance therapies groups for recurrence rate in patients with NMIBC. Participants, patients with NMIBC;Interventions,NMIBC patients who underwent intravesical BCG therapy;Outcomes, comparison of recurrence rate included for analysis. Quality assessmentswere performed independently by two reviewers using the Scottish Intercollegiate Guidelines Network.Results: Nineteen studies with a total of 3,957 patients were included for network meta-analysis. 19 studies were intermediate risk for detectionbias and there were no major problems. There was just two published studies between M1 and MM1. Five studies between No_M and M1 and 12articles between No_M and MM1 were identified. In node-split forest plot using Bayesian Markov Chain Monte Carlo (MCMC) modeling, there couldbe no difference between M1 and MM1 in recurrence rate (OR 0.95 (0.73-1.2)). However, recurrence rate in No_M group was higher than M1 (OR1.9 (1.5-2.5)) and MM1 (OR 2.0 (1.7-2.4)) groups (Fig. 1A). P-score test using frequentist method to rank treatments in network demonstrate MM1(P-score 0.8701) was superior to M1 (P-score 0.6299) and No_M groups (P-score 0). In the rank-probability test using MCMC modeling, MM1 had the highest rank, followed by M1 and No_M groups (Fig. 1B). (Figure Presented)(Figure Presented)Conclusions: In network meta-analysis, there could be no difference between 1-year and more than 1-year maintenance intravesical BCGtherapies in recurrence rate. In the rank test, more than 1-year therapy could be most effective. During COVID-19 pandemic, 1-year maintenancetherapy can be performed, however, after the COVID-19 pandemic, more than 1-year therapy will be decided